Pioneering technology for protein production

During our last financial year progress against our strategic objectives included:

• Made further submissions as part of the process for regulatory approval of PRRSv-resistant animals in the US, while working with regulatory bodies and agencies in other target markets around the world
• Advanced our project focused on swine influenza and evaluated opportunities for using gene editing to combat ASF, both in collaboration with Kansas State University

• Continued to improve the quality, fertility and number of gender skews delivered through our proprietary bovine sexing technology
• Began using specialist technology in some of our laboratories to increase the ratio of Y chromosomes in straws of sexed semen, with the aim of producing more male offspring
• Established a new IntelliGen Technologies laboratory with a customer, giving us 12 owned and licensed facilities around the world

• Introduced a new medium for embryo culture, to further improve quality and quantity, and harnessed leading-edge technology to enable the identification of the sex of embryos before transfer to recipients
• Continued to work internally and in collaboration with University of California Davis and Missouri State University to explore the role embryonic stem cells could play in enhancing genetic gain

• Accelerated implementation of our data analytics strategy, making strong progress on initiatives including rapid data inception, data integration, scalable hybrid computing and flexible data storage